These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28569268)

  • 21. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
    Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
    Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ezetimibe offers new opportunity to lower LDL-C to target levels.
    Cardiovasc J S Afr; 2005; 16(3):174. PubMed ID: 16049593
    [No Abstract]   [Full Text] [Related]  

  • 23. Looking into the crystal ball-upcoming drugs for dyslipidemia.
    George M; Selvarajan S; Muthukumar R; Elangovan S
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):11-20. PubMed ID: 25079474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
    Eyvazian VA; Frishman WH
    Cardiol Rev; 2017; 25(2):43-52. PubMed ID: 28099220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 27. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
    Briand F; Thieblemont Q; Muzotte E; Sulpice T
    Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid Management Steps Forward.
    Siegel JA
    J S C Med Assoc; 2015 Dec-2016 Jan; 111(4):122-5. PubMed ID: 27141703
    [No Abstract]   [Full Text] [Related]  

  • 30. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LDL levels in diabetes: how low should they go?
    Tovar JM; Bazaldua OV; Poursani RS
    J Fam Pract; 2007 Aug; 56(8):634-40. PubMed ID: 17669288
    [No Abstract]   [Full Text] [Related]  

  • 33. CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.
    Tardif JC; Rhainds D; Rhéaume E; Dubé MP
    Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):396-400. PubMed ID: 28126828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-density lipoprotein cholesterol as the Holy Grail.
    Cannon CP
    JAMA; 2011 Nov; 306(19):2153-5. PubMed ID: 22089726
    [No Abstract]   [Full Text] [Related]  

  • 35. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
    Hey SP; Franklin JM; Avorn J; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2017 Jun; 10(6):. PubMed ID: 28611186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk.
    Barter PJ; Rye KA
    Cardiol Clin; 2018 May; 36(2):299-310. PubMed ID: 29609759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial: collecting new external evidence for cholesterol management.
    Streja D
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):121-3. PubMed ID: 26863279
    [No Abstract]   [Full Text] [Related]  

  • 40. Forecasting cholesterol management--end of the statin gold rush?
    Crownover BK; Curtiss FR
    J Manag Care Pharm; 2006; 12(6):479-85. PubMed ID: 16925456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.